Dynavax Technologies Corporation
DVAXNASDAQHealthcare
$15.50
+$0.00(+0.00%)
Market Cap$1.8B
P/E Ratio—
52W High$15.73
52W Low$9.2
Dynavax Technologies Corporation (DVAX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
DVAX · earnings · updated Jun 8, 2026
Latest Earnings
Q1 FY2026Report Date: Feb 19, 2026EPS Actual
$0.05
Est. $0.08 · -38.5%
Revenue
—
Est. $0.08B
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Feb 19, 2026
After Market Close
▼ Miss EPS
DVAX reports quarterly as a NASDAQ-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q1 FY2026 | Feb 19, 2026 | $0.08 | $0.05 | -38.5% | — | $0.08B | — |
| ▲ Q4 FY2025 | Nov 5, 2025 | $0.14 | $0.21 | +50.0% | $0.09B | $0.08B | +18.2% |
| ▲ Q3 FY2025 | Aug 7, 2025 | $0.12 | $0.14 | +16.7% | $0.10B | $0.09B | +1.5% |
| ▼ Q2 FY2025 | May 6, 2025 | $0.03 | -$0.11 | -466.7% | $0.07B | $0.08B | -19.0% |
| — Q1 FY2025 | Feb 20, 2025 | $0.05 | $0.05 | +0.0% | $0.07B | $0.07B | -0.9% |
| ▲ Q4 FY2024 | Nov 7, 2024 | $0.11 | $0.12 | +9.1% | $0.08B | $0.07B | +12.4% |
| ▲ Q3 FY2024 | Aug 6, 2024 | $0.06 | $0.08 | +33.3% | $0.07B | $0.08B | -3.0% |
| ▼ Q2 FY2024 | May 8, 2024 | -$0.05 | -$0.07 | -40.0% | $0.05B | $0.05B | -7.6% |
Q1 FY2026
Feb 19, 2026Miss
EPS Actual
$0.05
EPS Est.
$0.08
EPS Surpr.
-38.5%
Revenue
—
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
$0.21
EPS Est.
$0.14
EPS Surpr.
+50.0%
Revenue
$0.09B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
$0.14
EPS Est.
$0.12
EPS Surpr.
+16.7%
Revenue
$0.10B
Q2 FY2025
May 6, 2025Miss
EPS Actual
-$0.11
EPS Est.
$0.03
EPS Surpr.
-466.7%
Revenue
$0.07B
Q1 FY2025
Feb 20, 2025
EPS Actual
$0.05
EPS Est.
$0.05
EPS Surpr.
+0.0%
Revenue
$0.07B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
$0.12
EPS Est.
$0.11
EPS Surpr.
+9.1%
Revenue
$0.08B
Q3 FY2024
Aug 6, 2024Beat
EPS Actual
$0.08
EPS Est.
$0.06
EPS Surpr.
+33.3%
Revenue
$0.07B
Q2 FY2024
May 8, 2024Miss
EPS Actual
-$0.07
EPS Est.
-$0.05
EPS Surpr.
-40.0%
Revenue
$0.05B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.18 | $0.18 | $0.18 | 1 |
| Q3 FY2027 | $0.31 | $0.31 | $0.31 | 1 |
| Q2 FY2027 | $0.29 | $0.29 | $0.29 | 1 |
| Q1 FY2027 | $0.18 | $0.18 | $0.18 | 1 |
| Q4 FY2026 | $0.07 | $0.07 | $0.07 | 1 |
| Q3 FY2026 | $0.23 | $0.23 | $0.23 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2026 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2026 | Feb 19, 2026 | -38.5% | $15.50 | — | — |
| ▲ Q4 FY2025 | Nov 5, 2025 | +50.0% | $10.05 | $10.30 | +2.49% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +16.7% | $11.19 | $11.06 | -1.16% |
| ▼ Q2 FY2025 | May 6, 2025 | -466.7% | $11.26 | $10.92 | -3.02% |
| ▲ Q1 FY2025 | Feb 20, 2025 | +0.0% | $13.09 | $13.33 | +1.83% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +9.1% | $12.29 | $12.02 | -2.20% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +33.3% | $10.07 | $10.05 | -0.20% |
| ▼ Q2 FY2024 | May 8, 2024 | -40.0% | $11.76 | $11.65 | -0.94% |
Q1 FY2026—
Report Date
Feb 19, 2026
EPS Beat/Miss
-38.5%
Price Before
$15.50
Price After
—
Q4 FY2025+2.49%
Report Date
Nov 5, 2025
EPS Beat/Miss
+50.0%
Price Before
$10.05
Price After
$10.30
Q3 FY2025-1.16%
Report Date
Aug 7, 2025
EPS Beat/Miss
+16.7%
Price Before
$11.19
Price After
$11.06
Q2 FY2025-3.02%
Report Date
May 6, 2025
EPS Beat/Miss
-466.7%
Price Before
$11.26
Price After
$10.92
Q1 FY2025+1.83%
Report Date
Feb 20, 2025
EPS Beat/Miss
+0.0%
Price Before
$13.09
Price After
$13.33
Q4 FY2024-2.20%
Report Date
Nov 7, 2024
EPS Beat/Miss
+9.1%
Price Before
$12.29
Price After
$12.02
Q3 FY2024-0.20%
Report Date
Aug 6, 2024
EPS Beat/Miss
+33.3%
Price Before
$10.07
Price After
$10.05
Q2 FY2024-0.94%
Report Date
May 8, 2024
EPS Beat/Miss
-40.0%
Price Before
$11.76
Price After
$11.65
Avg Beat Reaction+0.15%
Avg Miss Reaction-1.98%
Beat Rate5 / 8 quarters
Largest Move-3.02% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: DVAX ends December
Dynavax Technologies Corporation (DVAX) most recently reported earnings on February 19, 2026 for Q1 FY2026, posting EPS of $0.05 — missing the analyst consensus of $0.08 by -38.5%. The next DVAX earnings date is expected around September 1, 2026.
Each quarter, investors track DVAX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. DVAX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
DVAX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
DVAX earnings · 5 questionsDynavax Technologies Corporation's next earnings report is expected around September 1, 2026. DVAX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; DVAX historically reports after market close (AMC).
DVAX earnings datewhen is DVAX earningsDVAX next earnings datewhen does DVAX report earningsDVAX earnings calendar
▸ Source: FMP · Dynavax Technologies Corporation SEC filings · US GAAP · Dynavax Technologies Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026